Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery.
Astrazeneca Plc (AZN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Gotham Asset Management Joel Greenblatt | 0 | $0 | 0% | |
| 2. | NWI Management Hari Hariharan | 0 | $0 | 0% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.78 | 11,893 | $2,209,481.54 | 19,262 | 2026-05-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 487,420 | $92,316,944 | 0.79% | |
| 2. | 179,593 | $34,054,410 | 0.08% | |
| 3. | 46,736 | $8,862,080 | 1.35% | |
| 4. | 44,270 | $8,284,761 | 0.86% | |
| 5. | 23,593 | $4,473,705 | 0.45% |
News See All
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn't Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S.
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected.
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated...
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol-Myers Squi...
AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal
British drugmaker AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) are in early talks about a potential merger that could create a $40...
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunity
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter can be downloaded here.
Can AstraZeneca PLC (AZN) Grow Its Rare Disease Portfolio Through Ultomiris Expansion?
TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S.
10 Best Weight Loss Drug Stocks to Buy in 2026
The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
12 Best Growth Stocks Trading in Oversold Territory
On June 11, Emily Roland, the Co-Chief Investment Strategist at Manulife John Hancock Investment Management, joined 'Squawk Box' on CNBC to discuss where investors can find opportunity right now.
Hedge Fund Resource Center